Sparrow Pharmaceuticals
Jeff joined Sparrow after a 26-year career at Abbott and AbbVie. Prior to that, Jeff spent three years in biotech clinical and regulatory at XOMA Corporation. Jeff has a broad foundation of knowledge in drug development ranging from Ph 1-4 clinical development across multiple therapeutic areas, cross-functional team management, and project planning, monitoring and reporting. He had direct involvement in the creation of two entirely new departments (Pharmacogenetics and Marketed Product Development), and the establishment of the US Medical Affairs Program and Portfolio Management function. Jeff holds BS and MS degrees in Bacteriology from the University of Wisconsin-Madison and worked in direct patient care and clinical research at the University Hospital.
Jeff enjoys spending time with his family and friends, is a private pilot, loves all things outdoors including fishing, hunting, camping, and loves fixing things!
This person is not in any offices
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.